Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

XSSC:600196 Stock Report

Market Cap: CN¥58.1b

Shanghai Fosun Pharmaceutical (Group) Valuation

Is 600196 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600196 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CN¥20.26
Fair Value
19.6% overvalued intrinsic discount
5
Number of Analysts

Below Fair Value: 600196 (CN¥24.23) is trading above our estimate of fair value (CN¥20.26)

Significantly Below Fair Value: 600196 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600196?

Key metric: As 600196 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600196. This is calculated by dividing 600196's market cap by their current earnings.
What is 600196's PE Ratio?
PE Ratio30.5x
EarningsCN¥2.11b
Market CapCN¥58.13b

Price to Earnings Ratio vs Peers

How does 600196's PE Ratio compare to its peers?

The above table shows the PE ratio for 600196 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.7x
600085 Beijing Tongrentang
31.9x14.7%CN¥51.8b
002422 Sichuan Kelun Pharmaceutical
14.8x10.6%CN¥43.5b
000999 China Resources Sanjiu Medical & Pharmaceutical
16.5x11.2%CN¥55.9b
000538 Yunnan Baiyao GroupLtd
23.8x11.3%CN¥102.7b
600196 Shanghai Fosun Pharmaceutical (Group)
30.5x29.1%CN¥58.1b

Price-To-Earnings vs Peers: 600196 is expensive based on its Price-To-Earnings Ratio (30.5x) compared to the peer average (21.7x).

Price to Earnings Ratio vs Industry

How does 600196's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600196 30.5xIndustry Avg. 28.8xNo. of Companies28PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600196 is expensive based on its Price-To-Earnings Ratio (30.5x) compared to the CN Pharmaceuticals industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is 600196's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600196 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.5x
Fair PE Ratio36.5x

Price-To-Earnings vs Fair Ratio: 600196 is good value based on its Price-To-Earnings Ratio (30.5x) compared to the estimated Fair Price-To-Earnings Ratio (36.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600196 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥24.23
CN¥27.17
+12.1%
12.7%CN¥31.00CN¥23.05n/a5
Jan ’26CN¥24.85
CN¥27.17
+9.3%
12.7%CN¥31.00CN¥23.05n/a5
Dec ’25CN¥26.68
CN¥27.69
+3.8%
14.8%CN¥34.50CN¥23.05n/a6
Nov ’25CN¥26.51
CN¥27.69
+4.5%
14.8%CN¥34.50CN¥23.05n/a6
Oct ’25CN¥27.67
CN¥27.29
-1.4%
15.4%CN¥34.50CN¥22.64n/a6
Sep ’25CN¥22.54
CN¥27.67
+22.8%
15.1%CN¥34.50CN¥22.64n/a6
Aug ’25CN¥23.60
CN¥27.87
+18.1%
14.1%CN¥34.50CN¥24.04n/a6
Jul ’25CN¥22.13
CN¥28.61
+29.3%
15.3%CN¥35.00CN¥24.50n/a6
Jun ’25CN¥23.17
CN¥28.61
+23.5%
15.3%CN¥35.00CN¥24.50n/a6
May ’25CN¥23.67
CN¥29.44
+24.4%
14.5%CN¥35.00CN¥24.50n/a6
Apr ’25CN¥23.45
CN¥31.18
+33.0%
17.5%CN¥38.70CN¥24.50n/a6
Mar ’25CN¥24.77
CN¥32.03
+29.3%
15.6%CN¥38.70CN¥24.50n/a6
Feb ’25CN¥22.27
CN¥32.94
+47.9%
11.9%CN¥38.70CN¥28.68n/a6
Jan ’25CN¥25.03
CN¥33.57
+34.1%
10.3%CN¥38.70CN¥30.00CN¥24.856
Dec ’24CN¥27.98
CN¥33.57
+20.0%
10.3%CN¥38.70CN¥30.00CN¥26.686
Nov ’24CN¥28.22
CN¥33.91
+20.1%
9.7%CN¥38.70CN¥30.00CN¥26.516
Oct ’24CN¥28.60
CN¥36.65
+28.1%
28.0%CN¥54.00CN¥19.04CN¥27.676
Sep ’24CN¥28.01
CN¥37.41
+33.6%
25.1%CN¥54.00CN¥19.04CN¥22.547
Aug ’24CN¥31.53
CN¥40.24
+27.6%
18.1%CN¥54.00CN¥28.69CN¥23.607
Jul ’24CN¥30.90
CN¥40.95
+32.5%
17.3%CN¥54.00CN¥28.69CN¥22.137
Jun ’24CN¥30.60
CN¥40.95
+33.8%
17.3%CN¥54.00CN¥28.69CN¥23.177
May ’24CN¥31.70
CN¥41.08
+29.6%
16.3%CN¥54.00CN¥28.69CN¥23.678
Apr ’24CN¥32.39
CN¥40.96
+26.5%
16.4%CN¥54.00CN¥28.69CN¥23.458
Mar ’24CN¥33.97
CN¥41.88
+23.3%
16.5%CN¥54.00CN¥30.94CN¥24.777
Feb ’24CN¥34.23
CN¥43.59
+27.3%
17.6%CN¥54.00CN¥30.94CN¥22.277
Jan ’24CN¥35.24
CN¥44.31
+25.7%
19.8%CN¥59.00CN¥30.94CN¥25.037
Analyst Price Target
Consensus Narrative from 5 Analysts
CN¥27.17
Fair Value
10.8% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 14:31
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Yang HuangBofA Global Research